We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Home-Based Treatment for Asthma

By HospiMedica staff writers
Posted on 25 Oct 2005
Children with asthma who received a new home-based environmental intervention program had 19% fewer unscheduled clinic visits, a 13% reduction in the use of albuterol inhalers, and 38 more symptom-free days over two years than children in a control group.

The home-based program targeted six major classes of allergens that trigger asthma symptoms: dust mites, cockroaches, pet dander, rodents, passive smoking, and mold. More...
Treatment was tailored to each child's sensitivity to the selected allergens and evidence of exposure to the specific triggers. During home visits, subjects were instructed on measures for reducing or eliminating allergen levels in the home. These included allergen-permeable covers on a mattress and pillows, air purifiers with particulate air (HEPA) filters, vacuum cleaners equipped with HEPA filters, and professional pest control.

"The findings of this study will enable policy makers and healthcare providers to more effectively allocate resources to achieve maximum benefits,” said Peter J. Gergen, M.D.. M.P.H., of the U.S. National Institute of Allergy and Infectious Diseases (NIAID; Bethesda, MD, USA), which helped to fund the study.

The study's results showed that this treatment cost only about U.S.$27.57 per symptom-free day, as cost-effective as many drug interventions. Data also showed that the cost would be substantially lower if the interventions were implemented in a community setting. The study was published in the October 11, 2005, online issue of the Journal of Allergy and Clinical Immunology.




Related Links:
.S. National Institute of Allergy and Infectious Diseases

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.